Clinical trialNCT00665353CompletedPhase 2Interventional

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment19HIV-1 and Hepatitis C Co-Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of this study is to determine whether treatment with pioglitazone prior to HCV treatment with peginterferon and ribavirin is safe and effective in improving the treatment outcome in insulin-resistant, HIV/HCV-coinfected people for whom previous treatment with peginterferon and ribavirin was unsuccessful.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kristen Marks, MD, MS
New York Presbyterian Hospital-Cornell
Principal Investigator
clinicaltrials.gov ↗
Marshall Glesby, MD, PhD
Cornell Clinical Trials Unit, Weill Medical College of Cornell University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf Aids Crs (801)
San Francisco, California, United States
Northwestern University Crs (2701)
Chicago, Illinois, United States
New Jersey Medical School-Adult Clinical Research Ctr. Crs (31477)
Newark, New Jersey, United States
Cornell Crs (7804)
New York, New York, United States
Ny Univ. Hiv/aids Crs (401)
New York, New York, United States
Aids Care Crs (1108)
Rochester, New York, United States
Metro Health Crs (2503)
Cleveland, Ohio, United States
Virginia Commonwealth Univ. Medical Ctr. Crs (31475)
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PEGINTERFERONPioglitazone →Ribavirin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2009
Primary completion: 31 May 2011
Completion: 31 Dec 2011
Last update posted: 12 Oct 2018
Registered enrollment: 19
Registry id: NCT00665353

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.